<p>Avoro Capital Advisors LLC 在第四季度根據最新提交給證券交易委員會的 13F 申報文件，將其持有的 Taysha Gene Therapies, Inc.（納斯達克股票代碼：TSHA）股份增加了 11.0%。該公司在該時期購買了額外的 430,555 股，持有公司股票的股份數為 4,355,555 股。根據最新的 SEC 申報，Avoro Capital Advisors LLC 持有 Taysha Gene Therapies 約價值$7,709,000 的股份。</p>
<p>獲取 <strong>Taysha Gene Therapies</strong> 警報：</p>
<ul>
<li>3 家小市值股票，適合您的秋季購物清單</li>
</ul>
<p>其他幾家機構投資者和對沖基金也調整了他們對 TSHA 的持股。花旗集團在第三季度收購了 Taysha Gene Therapies 的新股份，價值$888,000。FMR LLC 在第三季度增加了其對 Taysha Gene Therapies 的持股，增幅達到 2,035.0%。FMR LLC 現在擁有公司股票的 24,527,801 股，價值$77,508,000，較上一季度增加了 23,378,974 股。EAM Investors LLC 在第三季度收購了 Taysha Gene Therapies 的新頭寸，價值$1,060,000。Acuta Capital Partners LLC 在第三季度購買了 Taysha Gene Therapies 的新頭寸，價值約$12,096,000。最後，Vanguard Group Inc.在第三季度將其對 Taysha Gene Therapies 的持股增加了 235.2%。Vanguard Group Inc.現在擁有公司股票的 5,327,864 股，價值$16,836,000，較上一季度增加了 3,738,616 股。目前，77.70% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>Taysha Gene Therapies 股價表現</h2>
<p>Taysha Gene Therapies 股票在週一的午盤交易中下跌了$0.03，報$3.92。該公司的交易量為 1,005,530 股，相比其平均交易量 2,383,907 股有所下降。該公司的流動比率為 3.38，速動比率為 3.38，負債權益比為 0.75。該公司的市值為$7.3312 億，市盈率為-8.00，貝塔係數為 0.49。該股的五十天簡單移動平均線為$2.85，二百天簡單移動平均線為$2.28。Taysha Gene Therapies, Inc.的一年最低價為$0.50，最高價為$4.02。</p>
<p>Taysha Gene Therapies（納斯達克股票代碼：TSHA）最近發佈了其季度財報，報告顯示，截至 5 月 14 日的週二，公司每股虧損為 ($0.10)，超過了分析師預期的 ($0.11)。Taysha Gene Therapies 的淨利潤率為-833.60%，淨資產收益率為-782.81%。該季度，公司營收為$3.41 百萬，略低於分析師預期的$3.70 百萬。去年同期，公司每股虧損為 ($0.28)。作為一個整體，股票研究分析師預測，Taysha Gene Therapies, Inc.今年將實現每股-0.43 的虧損。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究分析師最近對 TSHA 發表了評論。Piper Sandler 在 4 月 9 日的研究報告中對 Taysha Gene Therapies 進行了覆蓋。他們給予公司 “超配” 評級，併為該公司設定了$9.00 的目標股價。Needham &amp; Company LLC 在 5 月 15 日的研究報告中重申了對 Taysha Gene Therapies 的 “買入” 評級，並設定了$7.00 的股價目標。Cantor Fitzgerald 在 5 月 28 日的研究報告中重申了對 Taysha Gene Therapies 的 “超配” 評級，並設定了$7.00 的股價目標。Chardan Capital 將 Taysha Gene Therapies 的股價目標從$5.00 上調至$7.00，並給予該股 “買入” 評級。最後，JMP Securities 重申了對 Taysha Gene Therapies 的 “市場跑贏” 評級，並在 3 月 20 日的研究報告中設定了$5.00 的目標股價。根據 MarketBeat.com 的數據，共有九位研究分析師對該股票給予買入評級。Taysha Gene Therapies 目前的共識評級為 “買入”，共識目標股價為$7.00。</p>
<p><strong>閲讀我們關於 TSHA 的最新研究報告</strong></p>
<h2>Taysha Gene Therapies 簡介（免費報告）</h2>
<p>Taysha Gene Therapies, Inc.是一家基因療法公司，專注於開發和商業化基於腺相關病毒的基因療法，用於治療中樞神經系統的單基因疾病。其主要開發項目包括用於治療巨大軸突神經病的 TSHA-120；用於治療雷特綜合徵的 TSHA-102；用於治療 CLN7 病的 TSHA-121；用於治療 CLN1 病的 TSHA-118；用於治療 SLC13A5 缺乏症的 TSHA-105；用於治療 tau 蛋白病的 TSHA-113；用於治療安吉曼綜合徵的 TSHA-106；用於治療脆性 X 綜合徵的 TSHA-114；以及用於治療 GM2 神經節苷脂病的 TSHA-101。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票，比 Taysha Gene Therapies 更好</li>
<li>投資高市盈率增長股</li>
<li>我們的全面風險承受能力評估</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>Autodesk 在完成審計調查後提高了業績指引</li>
<li>如何閲讀股票圖表，適合初學者</li>
<li>Lyft 股票在投資者日發佈大膽的 2027 年業績指引後出現跳空和垃圾股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 是時候擺脱中國的鋰了！（來自 Smallcaps Daily）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw"/></p>
<h2>您現在是否應該投資$1,000 購買 Taysha Gene Therapies？</h2>
<p>在考慮購買 Taysha Gene Therapies 之前，您需要聽聽這個建議。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票，然後等待整個市場的關注... 而 Taysha Gene Therapies 並不在這份名單上。</p>
<p>儘管 Taysha Gene Therapies 目前在分析師中有一個&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

TSHA

<p>Avoro Capital Advisors LLC 根據最近向證券交易委員會提交的文件，在第四季度增加了對 Taysha Gene Therapies 的持股比例，增幅為 11%。Avoro Capital Advisors 現在擁有該公司 435 萬 5555 股的股份，價值 770 萬美元。其他機構投資者和對沖基金也調整了他們對 TSHA 的持股。Taysha Gene Therapies 是一家專注於開發中樞神經系統單基因疾病治療的基因治療公司</p>

<p>Avoro Capital Advisors LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.0% in the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 4,355,555 shares of the company's stock after buying an additional 430,555 shares during the period. Avoro Capital Advisors LLC owned about 2.33% of Taysha Gene Therapies worth $7,709,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Avoro Capital Advisors LLC 在第四季度根據最新提交給證券交易委員會的 13F 申報文件，將其持有的 Taysha Gene Therapies, Inc.（納斯達克股票代碼：TSHA）股份增加了 11.0%。該公司在該時期購買了額外的 430,555 股，持有公司股票的股份數為 4,355,555 股。根據最新的 SEC 申報，Avoro Capital Advisors LLC 持有 Taysha Gene Therapies 約價值$7,709,000 的股份。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Taysha Gene Therapies</strong> 警報：</p>
<ul>
<li>3 家小市值股票，適合您的秋季購物清單</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also modified their holdings of TSHA. Citigroup Inc. acquired a new stake in Taysha Gene Therapies during the third quarter valued at $888,000. FMR LLC raised its holdings in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company's stock valued at $77,508,000 after purchasing an additional 23,378,974 shares in the last quarter. EAM Investors LLC acquired a new position in Taysha Gene Therapies during the third quarter worth $1,060,000. Acuta Capital Partners LLC bought a new position in Taysha Gene Therapies during the third quarter valued at about $12,096,000. Finally, Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company's stock worth $16,836,000 after purchasing an additional 3,738,616 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金也調整了他們對 TSHA 的持股。花旗集團在第三季度收購了 Taysha Gene Therapies 的新股份，價值$888,000。FMR LLC 在第三季度增加了其對 Taysha Gene Therapies 的持股，增幅達到 2,035.0%。FMR LLC 現在擁有公司股票的 24,527,801 股，價值$77,508,000，較上一季度增加了 23,378,974 股。EAM Investors LLC 在第三季度收購了 Taysha Gene Therapies 的新頭寸，價值$1,060,000。Acuta Capital Partners LLC 在第三季度購買了 Taysha Gene Therapies 的新頭寸，價值約$12,096,000。最後，Vanguard Group Inc.在第三季度將其對 Taysha Gene Therapies 的持股增加了 235.2%。Vanguard Group Inc.現在擁有公司股票的 5,327,864 股，價值$16,836,000，較上一季度增加了 3,738,616 股。目前，77.70% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Taysha Gene Therapies Price Performance</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股價表現</h2>
</div><p>Shares of Taysha Gene Therapies stock traded down $0.03 during midday trading on Monday, reaching $3.92. The company had a trading volume of 1,005,530 shares, compared to its average volume of 2,383,907. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $733.12 million, a price-to-earnings ratio of -8.00 and a beta of 0.49. The stock has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $2.28. Taysha Gene Therapies, Inc. has a 1-year low of $0.50 and a 1-year high of $4.02.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 股票在週一的午盤交易中下跌了$0.03，報$3.92。該公司的交易量為 1,005,530 股，相比其平均交易量 2,383,907 股有所下降。該公司的流動比率為 3.38，速動比率為 3.38，負債權益比為 0.75。該公司的市值為$7.3312 億，市盈率為-8.00，貝塔係數為 0.49。該股的五十天簡單移動平均線為$2.85，二百天簡單移動平均線為$2.28。Taysha Gene Therapies, Inc.的一年最低價為$0.50，最高價為$4.02。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The business had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same quarter last year, the business posted ($0.28) earnings per share. As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（納斯達克股票代碼：TSHA）最近發佈了其季度財報，報告顯示，截至 5 月 14 日的週二，公司每股虧損為 ($0.10)，超過了分析師預期的 ($0.11)。Taysha Gene Therapies 的淨利潤率為-833.60%，淨資產收益率為-782.81%。該季度，公司營收為$3.41 百萬，略低於分析師預期的$3.70 百萬。去年同期，公司每股虧損為 ($0.28)。作為一個整體，股票研究分析師預測，Taysha Gene Therapies, Inc.今年將實現每股-0.43 的虧損。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research analysts recently commented on TSHA shares. Piper Sandler initiated coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an &#34;overweight&#34; rating and a $9.00 target price for the company. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, May 15th. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, May 28th. Chardan Capital raised their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 21st. Finally, JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $7.00.</p>
<div class="lb-trans"><p>一些研究分析師最近對 TSHA 發表了評論。Piper Sandler 在 4 月 9 日的研究報告中對 Taysha Gene Therapies 進行了覆蓋。他們給予公司 “超配” 評級，併為該公司設定了$9.00 的目標股價。Needham &amp; Company LLC 在 5 月 15 日的研究報告中重申了對 Taysha Gene Therapies 的 “買入” 評級，並設定了$7.00 的股價目標。Cantor Fitzgerald 在 5 月 28 日的研究報告中重申了對 Taysha Gene Therapies 的 “超配” 評級，並設定了$7.00 的股價目標。Chardan Capital 將 Taysha Gene Therapies 的股價目標從$5.00 上調至$7.00，並給予該股 “買入” 評級。最後，JMP Securities 重申了對 Taysha Gene Therapies 的 “市場跑贏” 評級，並在 3 月 20 日的研究報告中設定了$5.00 的目標股價。根據 MarketBeat.com 的數據，共有九位研究分析師對該股票給予買入評級。Taysha Gene Therapies 目前的共識評級為 “買入”，共識目標股價為$7.00。</p>
</div><p><strong>Read Our Latest Research Report on TSHA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TSHA 的最新研究報告</strong></p>
</div><h2>Taysha Gene Therapies Profile (Free Report)</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 簡介（免費報告）</h2>
</div><p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc.是一家基因療法公司，專注於開發和商業化基於腺相關病毒的基因療法，用於治療中樞神經系統的單基因疾病。其主要開發項目包括用於治療巨大軸突神經病的 TSHA-120；用於治療雷特綜合徵的 TSHA-102；用於治療 CLN7 病的 TSHA-121；用於治療 CLN1 病的 TSHA-118；用於治療 SLC13A5 缺乏症的 TSHA-105；用於治療 tau 蛋白病的 TSHA-113；用於治療安吉曼綜合徵的 TSHA-106；用於治療脆性 X 綜合徵的 TSHA-114；以及用於治療 GM2 神經節苷脂病的 TSHA-101。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Our Comprehensive Risk Tolerance Assessment</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Autodesk Raises Guidance After Clearing Audit Investigation</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Lyft Stock Gap and Craps on Bold 2027 Guidance at Investor Day</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票，比 Taysha Gene Therapies 更好</li>
<li>投資高市盈率增長股</li>
<li>我們的全面風險承受能力評估</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>Autodesk 在完成審計調查後提高了業績指引</li>
<li>如何閲讀股票圖表，適合初學者</li>
<li>Lyft 股票在投資者日發佈大膽的 2027 年業績指引後出現跳空和垃圾股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ It's time to ween off Chinese lithium! (From Smallcaps Daily)(Ad)</p>
<div class="lb-trans"><p>→ 是時候擺脱中國的鋰了！（來自 Smallcaps Daily）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8280&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Taysha Gene Therapies right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 購買 Taysha Gene Therapies？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Taysha Gene Therapies 之前，您需要聽聽這個建議。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票，然後等待整個市場的關注... 而 Taysha Gene Therapies 並不在這份名單上。</p>
</div><p>While Taysha Gene Therapies currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Taysha Gene Therapies 目前在分析師中有一個&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Avoro Capital Advisors LLC 在 Taysha Gene Therapies, Inc.（納斯達克股票代碼：TSHA）持有價值 771 萬美元的股票頭寸